Curated News
By: NewsRamp Editorial Staff
October 27, 2026
NanoViricides Advances Oral Ebola Bundibugyo Drug Trial in DRC
TLDR
- NanoViricides' NV-387 Oral Gummies is the only oral drug candidate in clinical trials for Ebola Bundibugyo, offering a first-mover advantage in an outbreak with over 10,000 cases.
- The Phase IIA trial enrolls about 20 patients to evaluate dosing by disease severity, with a primary endpoint of 28-day survival, then advances to Phase IIB.
- An oral treatment for Ebola Bundibugyo could improve access and outcomes in the DRC, where no approved therapies exist and outbreaks cause thousands of deaths.
- NanoViricides is testing NV-387 Oral Gummies for Ebola Bundibugyo in the DRC, where over 10,000 cases and 4,900 deaths have been reported.
Impact - Why it Matters
This news matters because Ebola Bundibugyo has no approved treatments or vaccines specifically targeting it, leaving health authorities with few options during an outbreak that has already produced more than 10,000 confirmed cases and roughly 4,900 deaths in the DRC. An oral antiviral could be far easier to deploy in resource-limited outbreak settings than injectable therapies, potentially simplifying distribution and early treatment. NanoViricides' progress also signals broader momentum for its nanoviricide platform, which the company is testing against mpox and positioning for respiratory viruses, meaning results here could inform development across multiple infectious diseases. For investors, the trial's advance to Phase IIB would mark a meaningful clinical milestone for a small-cap biotech whose pipeline depends on demonstrating its platform in human studies.
Summary
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, is advancing its Phase IIA clinical trial of NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus disease in the Democratic Republic of Congo. Enrollment in the study began on Sept. 23, 2026, with approximately 20 patients expected to participate in the initial phase, which is designed to evaluate dosing regimens based on disease severity. The trial's primary endpoint is 28-day survival, and the Phase IIA portion will conclude once the final enrolled patient completes the observation period, with advancement to Phase IIB anticipated thereafter.
The company emphasized the potential significance of an oral antiviral amid the ongoing Ebola Bundibugyo outbreak, citing more than 10,000 confirmed cases and approximately 4,900 deaths in the DRC. NanoViricides noted that no treatments or vaccines are currently approved specifically for Ebola Bundibugyo and that NV-387 Oral Gummies is, to its knowledge, the only oral drug candidate undergoing clinical evaluation for the disease. The company is also testing NV-387 Oral Gummies in a separate Phase II clinical trial for mpox in the DRC. Readers can view the full press release at https://ibn.fm/JJ69W.
NanoViricides describes itself as a clinical-stage company creating special purpose nanomaterials for antiviral therapy, with its nanoviricide(TM) drug candidates and technology based on intellectual property and know-how from TheraCour Pharma, Inc. Its lead candidate, NV-387, is a broad-spectrum antiviral being developed for RSV, COVID, Long COVID, influenza and other respiratory infections, as well as MPOX/smallpox and measles, while NV-HHV-1 targets shingles. The company holds a worldwide exclusive perpetual license to the TheraCour nanomedicine technology for several human viral diseases, including Ebola/Marburg viruses. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC, and the announcement was distributed through BioMedWire, part of the Dynamic Brand Portfolio at IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Advances Oral Ebola Bundibugyo Drug Trial in DRC
